Ana Ortega-Franco
Overview
Explore the profile of Ana Ortega-Franco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saldanha E, Nicolo E, Venetis K, de Miguel-Perez D, Ortega-Franco A, Dipasquale A, et al.
J Liq Biopsy
. 2025 Mar;
5:100156.
PMID: 40027940
No abstract available.
2.
Reduzzi C, Nicolo E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, et al.
Crit Rev Oncol Hematol
. 2024 Aug;
203:104483.
PMID: 39159706
Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological...
3.
Ortega-Franco A, Hodgson C, Raja H, Carter M, Lindsay C, Hughes S, et al.
Target Oncol
. 2022 Jul;
17(4):453-465.
PMID: 35781861
Background: Pembrolizumab is licensed for the treatment of pre-treated and PD-L1 positive non-small cell lung cancer (NSCLC), but response is heterogeneous. In this context, the Lung Immune Prognostic Index (LIPI)...
4.
Alese O, Cook N, Ortega-Franco A, Ulanja M, Tan L, Tie J
Am Soc Clin Oncol Educ Book
. 2022 Apr;
42:1-20.
PMID: 35471832
Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that has come from primary or metastatic cancer sites. Neoplasm-specific genetic and epigenetic abnormalities are increasingly being identified through...
5.
Ortega-Franco A, Rafee S
Oncol Ther
. 2022 Mar;
10(1):13-22.
PMID: 35294773
The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and...
6.
Hockenhull K, Ortega-Franco A, Califano R
Transl Lung Cancer Res
. 2021 Nov;
10(9):3850-3854.
PMID: 34733633
No abstract available.
7.
Ortega-Franco A, Calvo V, Franco F, Provencio M, Califano R
Transl Lung Cancer Res
. 2021 Jan;
9(6):2656-2673.
PMID: 33489825
Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated radically with surgery and (neo)adjuvant chemotherapy (Cht). The discovery of tyrosine kinase inhibitors (TKIs) for oncogene...
8.
Ackermann C, Adderley H, Ortega-Franco A, Khan A, Reck M, Califano R
Drugs
. 2020 Sep;
80(17):1783-1797.
PMID: 32986224
The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients...